Reference entry · Triple GLP-1/GIP/glucagon receptor agonist
Retatrutide
Also known as: LY3437943 · triple incretin agonist
- Class
- Triple GLP-1/GIP/glucagon receptor agonist
- Primary targets (literature)
- GLP-1, GIP, glucagon receptors
- Regulatory context
- Investigational — not FDA-approved. High catalog-demand development compound with variable COA quality.
Overview
Retatrutide is a development-stage triple agonist adding glucagon receptor activity to dual incretin pharmacology. Human data are earlier and narrower than for semaglutide or tirzepatide, with active phase 2 literature.
Mechanism in research literature
Triple receptor engagement introduces glucagon-mediated energy-expenditure and hepatic biology hypotheses alongside incretin pathways studied in dual agonists.
Common research focus areas
- Phase 2 obesity and T2D dose-ranging
- Glucagon pathway monitoring in trials
- Early-stage evidence vs. established GLP-1 drugs
- Triple-agonist identity and purity analytics
Full literature roundup
Read the cited research summary
A triple GLP-1/GIP/glucagon receptor agonist in early clinical research. Preclinical context, evidence gaps, and material evaluation.
Retatrutide research roundup · 5 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.